Twist Bioscience Stock News

Twist Bioscience Corporation (NASDAQ: TWST ) has priced its upsized underwritten public offering of 4.5 million at $55.00 per share , with gross proceeds of approximately $250 million. Earlier, the Company had announced the public offering of $200 million . The Offer price Full story available on Benzinga.com

Twist Bioscience (TWST) has priced an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00/share for an expected gross

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00 per share. The gross proceeds of the offering to Twist before deducting the underwriting discount and commissions and estimated offering expen

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Announces Publication Of Positive Late-Stage Data For Keytruda-Chemo Combo In Breast Cancer Merc

SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 8:00 a.m. Eastern Time. The presentation will be webcast li

Twist Bioscience (TWST) announced a proposed $200M underwritten public offering of shares.TWST intends to grant the underwriters a 30-day option to purchase up to $30M of…

Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe C2i to integrate Twist’s library preparation kits into minimal residual disease workflow NEW YORK &

Twist Bioscience Corp (NASDAQ: TWST ) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeutic development. Replicons are synthetic viral RNA molecules that mimic viruses in their ability to replicate but have been engineered to remove the portion … Full story available on Benzinga.com

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeut

Twist Bioscience's (TWST) CEO Emily Leproust on Q1 2022 Results - Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its sili

Twist Bioscience Corp  TWST reported a 49.2% Y/Y increase in its Q1 FY22 revenues to $42.02 million, beating the Wall Street estimate of $38.33 million and the management expectation of $37 million

Twist Bioscience (TWST) delivered earnings and revenue surprises of 15.74% and 10.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (NASDAQ:TWST) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is -$1.06 (-47.2% Y/Y) and the